Patents-Review.com
🔗 Permalink
Assignee profile:

KANCERA AB

City:

Solna

Country:

Sweden

Published Applications:

12

Last publication date:

2023-10-12

Patent Grants:

12

Last grant date:

2025-04-01

Top Inventors for applications by KANCERA AB

These are the the leading inventors for applications assigned to KANCERA AB:

Recent patent applications by KANCERA AB

KANCERA AB based in Solna, SE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2023-10-12 ✅ Patent 12,264,165 granted on 2025-04-01
US20230322807A1
Chemistry; metallurgy

Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom

 #2 | 2023-03-02 ✅ Patent 11,691,988 granted on 2023-07-04
US20230068240A1
Chemistry; metallurgy

Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom

 #3 | 2021-09-23 ✅ Patent 12,060,380 granted on 2024-08-13
US20210292349A1
Chemistry; metallurgy

Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1

 #4 | 2021-09-02 ✅ Patent 11,660,303 granted on 2023-05-30
US20210267994A1
Human necessities

2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity

 #5 | 2021-06-24 ✅ Patent 11,542,281 granted on 2023-01-03
US20210188873A1
Chemistry; metallurgy

Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom

 #6 | 2020-01-23 ✅ Patent 11,008,318 granted on 2021-05-18
US20200024272A1
Chemistry; metallurgy

2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity

 #7 | 2018-01-04 ✅ Patent 10,550,113 granted on 2020-02-04
US20180002329A1
Chemistry; metallurgy

2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity

 #8 | 2016-08-04 ✅ Patent 10,000,449 granted on 2018-06-19
US20160221938A1
Chemistry; metallurgy

Bisarylsulfonamides useful in the treatment of inflammation and cancer

 #9 | 2015-01-22 ✅ Patent 9,718,809 granted on 2017-08-01
US20150025068A1
Chemistry; metallurgy

Bisarylsulfonamides useful in the treatment of inflammation and cancer

 #10 | 2014-01-02 ✅ Patent 9,150,647 granted on 2015-10-06
US20140004156A1
Chemistry; metallurgy

Biological inhibitors of ROR1 capable of inducing cell death

 #11 | 2013-10-24 ✅ Patent 9,266,952 granted on 2016-02-23
US20130281922A1
Chemistry; metallurgy

Antibodies against ROR1 and uses thereof

 #12 | 2013-07-04 ✅ Patent 9,233,946 granted on 2016-01-12
US20130172339A1
Chemistry; metallurgy

Sulfonamide compounds

Also check out Kancera AB's (Solna, Sweden) applicant profile with 13 patent applications submitted.

AssigneeID:

29117 ⎘